Results 151 to 160 of about 87,925 (315)

Imatinib Mesylate and Gray Hair [PDF]

, 2002
Gabriel Étienne, Pascale Cony‐Makhoul, François‐Xavier Mahon   +2 more
openalex   +1 more source

The Efficacy of Pediatric‐Inspired Regimens vs. Hyper‐CVAD in the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Systematic Review and Meta‐Analysis

American Journal of Hematology, Volume 100, Issue 5, Page 847-859, May 2025.
ABSTRACT Adults with acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) have poorer outcomes than pediatric patients. The aim of this systematic literature review and meta‐analysis was to compare asparaginase (ASP)‐containing pediatric‐inspired regimens (PIRs) with hyper‐fractionated cyclophosphamide, vincristine, doxorubicin, and ...
Wenqing Su, Melisa Stricherz, Alison Martin, Jonathan Belsey, Eric Kemadjou, Daniel J. DeAngelo   +5 more
wiley   +1 more source

Serial monitoring of BCR–ABL by peripheral blood real‐time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia [PDF]

, 2002
Lihui Wang, Kevin Pearson, Lynne Pillitteri, Julia E. Ferguson, Richard E. Clark   +4 more
openalex   +1 more source

Advancing Therapeutic Drug Monitoring for Oral Targeted Anticancer Drugs: From Hospital‐Based Towards Home‐Sampling

Biomedical Chromatography, Volume 39, Issue 5, May 2025.
ABSTRACT Home‐sampling for therapeutic drug monitoring (TDM) for oral targeted anticancer drugs offers a promising alternative to traditional hospital‐based sampling methods, though it presents challenges. This review aims to summarize the state‐of‐the‐art of home‐sampling methods for TDM and evaluates the analytical and clinical validation challenges.
Marinda Meertens, Hilde Rosing, Neeltje Steeghs, Jos H. Beijnen, Alwin D. R. Huitema   +4 more
wiley   +1 more source

Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

Cell Biology International, Volume 49, Issue 5, Page 570-586, May 2025.
ABSTRACT Chronic Myeloid Leukemia (CML) is characterized by the BCR::ABL1 fusion gene, driving uncontrolled myeloid cell proliferation. Furthermore, metabolic dysregulation contributes to disease progression. Despite the efficacy of tyrosine kinase inhibitors (TKIs), unresolved clinical needs persist, necessitating refined preclinical models.
Alessia Cavalleri, Besjana Xhahysa, Silvia Mutti, Rosalba Monica Ferraro, Elena Laura Mazzoldi, Mirko Farina, Alessandro Leoni, Luca Garuffo, Federica Trenta, Federica Re, Vera Radici, Eugenia Accorsi Buttini, Enrico Morello, Gabriele Magliano, Valeria Cancelli, Silvia Clara Giliani, Michele Malagola, Domenico Russo, Simona Bernardi   +18 more
wiley   +1 more source

Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia [PDF]

, 2002
James C. Barton, S. Christopher Jones, Wade C. Lamberth, Michael T. Reymann, Varian C. Scott   +4 more
openalex   +1 more source

Characterization of NAT, GST, and CYP2E1 Genetic Variation in Sub‐Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases

Clinical Pharmacology &Therapeutics, Volume 117, Issue 5, Page 1338-1357, May 2025.
Tuberculosis (TB) is a major health burden in Africa. Although TB is treatable, anti‐TB drugs are associated with adverse drug reactions (ADRs), which are partly attributed to pharmacogenetic variation. The distribution of star alleles (haplotypes) influencing anti‐TB drug metabolism is unknown in many African populations.
Thandeka V.B. Malinga, Houcemeddine Othman, Maria Paximadis, Caroline T. Tiemessen, Michèle Ramsay, Scott Hazelhurst, David Twesigomwe   +6 more
wiley   +1 more source

Increased plasma imatinib exposure and toxicity in chronically treated GIST patients with SARS-CoV-2 infection: a case series

Frontiers in Immunology
IntroductionInflammatory factors released during severe coronavirus disease-19 (COVID-19) caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are known to influence drug exposure, but data on the effect of mild infection are few.
Sara Gagno, Bianca Posocco, Marco Orleni, Eleonora Cecchin, Arianna Fumagalli, Michela Guardascione, Angela Buonadonna, Jerry Polesel, Fabio Puglisi, Fabio Puglisi, Giuseppe Toffoli, Erika Cecchin   +11 more
doaj   +1 more source

Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia [PDF]

, 2002
Hendrik W. van Deventer, Melissa D. Hall, Robert Z. Orlowski, Beverly S. Mitchell, Lee R. Berkowitz, Cathe Hogan, Cherie H. Dunphy, Julie Koehler, Thomas C. Shea   +8 more
openalex   +1 more source

α‐Synuclein in Parkinson's Disease: From Bench to Bedside

Medicinal Research Reviews, Volume 45, Issue 3, Page 909-946, May 2025.
ABSTRACT α‐Synuclein (α‐syn), a pathological hallmark of PD, is emerging as a bridging element at the crossroads between neuro/immune‐inflammatory responses and neurodegeneration in PD. Several evidence show that pathological α‐syn accumulates in neuronal and non‐neuronal cells (i.e., neurons, microglia, macrophages, skin cells, and intestinal cells ...
Gabriele Bellini, Vanessa D'Antongiovanni, Giovanni Palermo, Luca Antonioli, Matteo Fornai, Roberto Ceravolo, Nunzia Bernardini, Pascal Derkinderen, Carolina Pellegrini   +8 more
wiley   +1 more source